156 related articles for article (PubMed ID: 37908209)
21. The Efficacy of Denosumab in the Management of a Tibial Paediatric Aneurysmal Bone Cyst Compromised by Rebound Hypercalcaemia.
Harcus M; Aldridge S; Abudu A; Jeys L; Senniappan S; Morgan H; Pizer B
Case Rep Pediatr; 2020; 2020():8854441. PubMed ID: 33376615
[TBL] [Abstract][Full Text] [Related]
22. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
23. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
24. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
25. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
27. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child.
Mariz BALA; Migliorati CA; Alves FA; Penteado FM; Carvalho NP; Santos-Silva AR; Rocha AC
Spec Care Dentist; 2021 Jul; 41(4):519-525. PubMed ID: 33760257
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer.
Wang R; Rajanayagam S; Ngan J; Renouf DA
Calcif Tissue Int; 2022 Oct; 111(4):391-395. PubMed ID: 35809111
[TBL] [Abstract][Full Text] [Related]
29. Hypercalcemia after discontinuation of long-term denosumab treatment.
Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B
Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536
[TBL] [Abstract][Full Text] [Related]
30. Denosumab Therapy for Refractory Hypercalcemia Secondary to Squamous Cell Carcinoma of Skin in Epidermolysis Bullosa.
Giri D; Ramakrishnan R; Hayden J; Brook L; Das U; Mughal MZ; Selby P; Dharmaraj P; Senniappan S
World J Oncol; 2015 Apr; 6(2):345-348. PubMed ID: 29147430
[TBL] [Abstract][Full Text] [Related]
31. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
32. Denosumab in the management of Aneurysmal bone cyst.
Maximen J; Robin F; Tronchot A; Rossetti A; Ropars M; Guggenbuhl P
Joint Bone Spine; 2022 Jan; 89(1):105260. PubMed ID: 34481945
[TBL] [Abstract][Full Text] [Related]
33. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
34. Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.
Wang D; Tang X; Shi Q; Wang R; Ji T; Tang X; Guo W
Transl Pediatr; 2023 Mar; 12(3):470-486. PubMed ID: 37035391
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
[TBL] [Abstract][Full Text] [Related]
36. Denosumab for the treatment of primary pediatric osteoporosis.
Anastasilakis AD; Makras P; Doulgeraki A; Polyzos SA; Guarnieri V; Papapoulos SE
Osteoporos Int; 2021 Nov; 32(11):2377-2381. PubMed ID: 33987688
[TBL] [Abstract][Full Text] [Related]
37. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
38. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
39. Hypercalcemia: A Review.
Walker MD; Shane E
JAMA; 2022 Oct; 328(16):1624-1636. PubMed ID: 36282253
[TBL] [Abstract][Full Text] [Related]
40. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]